Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Chemomab Therapeutics Ltd. - American Depositary Shares
(NQ:
CMMB
)
1.410
+0.110 (+8.46%)
Delayed Quote
Updated: 1:41 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Chemomab Therapeutics Ltd. - American Depositary Shares
< Previous
1
2
Next >
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
August 31, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 19, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
July 08, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
March 19, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
December 02, 2025
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
November 24, 2025
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 20, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
November 06, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
August 21, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
June 30, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
June 11, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
June 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
May 05, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
April 28, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
April 21, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces New Medical and Clinical Appointments
April 15, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
March 27, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
March 06, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
March 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
February 19, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
December 03, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
November 19, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 14, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
October 30, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
October 15, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
